{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '11', 'REFERENCES', 'Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. European Organization', 'for Research and Treatment of Cancer Study Group on Quality of Life. The European', 'Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for', 'use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.', 'Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. KEYNOTE-045 Investigators.', 'Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med.', '2017;376:1015-26. DOI: 10.1056/NEJMoal613683.', 'Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V, et al. ESMO Guidelines Working', 'Group. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and', 'follow-up. Ann Oncol. 2011;22(S6):45-9.', 'Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of', 'vinflunine plus best supportive care compared with best supportive care alone after a platinum-', 'containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.', 'J Clin Oncol. 2009;27:4454-61.', 'Cancer Fact Sheets: All cancers excluding Non-Melanoma Skin. International Agency for Research', 'on Cancer 2017. Retrieved from http://gco.iarc.fr/today/fact-sheets-', 'cancers?cancer=29&type=0&sex=0. Accessed 19 Dec 2017.', 'Docetaxel summary of product characteristics. Jul 2014.', 'Fidalgo JA, Garcia Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F. Management of', 'chemotherapy extravasation: ESMO clinical practice guidelines. Ann Oncol. 2012;23(7):167-73.', 'Herdman M, Godex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development an preliminary', 'testing of the new-five level version of EQ-5D (EQ-5D-5L). Qual LifeRes. 2011;20(10):1727-36.', 'Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-', '63.', 'Mullane SA & Bellmunt J. Cancer immunotherapy: new applications in urologic oncology. Curr Opin', 'Urol. 2016;26:556-63.', 'Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response', 'criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.', 'Paclitaxel Amneal summary of product characteristics. Nov 2016.', 'Polovich M, Olsen M, LeFebvre K. Chemotherapy and biotherapy guidelines and recommendations', 'for practice. 4th ed. Pittsburgh: Oncology Nursing Society; 2014. 473 p.', 'Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al.', 'Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have', 'progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre,', 'phase 2 trial. Lancet 2016;387:1909-20.', '14 Sep 2020', 'Astellas', 'Page 101 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD,', 'http://seer.cancer.govstatfacts/html/urinb.html. Accessed 19 Dec 2017.', 'Sneeuw KC, Aaronson NK, Sprangers MA, Detmar SB, Wever LD, Schornagel JH. Comparison of', 'patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients. J', 'Clin Epidemiol. 1998;51:617-31.', 'von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival', 'results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate,', 'vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol.', '2005;23:4602-8.', 'Vinflunine (Javlor) summary of product characteristics.', '14 Sep 2020', 'Astellas', 'Page 102 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}